Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

标题
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15_suppl, Pages 9089-9089
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2018-09-05
DOI
10.1200/jco.2018.36.15_suppl.9089

向作者/读者发起求助以获取更多资源

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started